par Procter, Marion;Suter, Thomas;de Azambuja, Evandro 
;Dafni, U;van Dooren, Veerle;Muehlbauer, Susanne;Climent, Miguel Angel;Rechberger, Ernst;Liu, Walter Tsang-Wu;Toi, Masakazu;Coombes, Raoul Charles;Dodwell, David;Pagani, Olivia;Madrid, Jorge;Hall, Marcia;Chen, Shin-Cheh;Focan, Christian;Muscholl, Michael;van Veldhuisen, Dirk J;Piccart-Gebhart, Martine
Référence Journal of clinical oncology, 28, 21, page (3422-3428)
Publication Publié, 2010-07
;Dafni, U;van Dooren, Veerle;Muehlbauer, Susanne;Climent, Miguel Angel;Rechberger, Ernst;Liu, Walter Tsang-Wu;Toi, Masakazu;Coombes, Raoul Charles;Dodwell, David;Pagani, Olivia;Madrid, Jorge;Hall, Marcia;Chen, Shin-Cheh;Focan, Christian;Muscholl, Michael;van Veldhuisen, Dirk J;Piccart-Gebhart, Martine Référence Journal of clinical oncology, 28, 21, page (3422-3428)
Publication Publié, 2010-07
Article révisé par les pairs
| Résumé : | We investigated the incidence of cardiac adverse events in patients with early breast cancer in the Herceptin Adjuvant (HERA) trial who were treated with 1 year of trastuzumab after completion of (neo)adjuvant chemotherapy. |
